METAP1

Methionine aminopeptidase 1 · P53582 · METAP1 on Sugi Atlas →

60,120 patent compounds predicted against METAP1, 30,911 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Thiabendazole Thiabendazole (SCHEMBL19842) 1.00 9/20
SCHEMBL124947 SCHEMBL124947 1.00 8/20
Thiophanate Methyl Thiophanate Methyl (SCHEMBL80466) 0.59 8/20
SCHEMBL125251 SCHEMBL125251 0.57 8/20
SCHEMBL125289 SCHEMBL125289 0.56 8/20
SCHEMBL124347 SCHEMBL124347 0.53 8/20
Cambendazole Cambendazole (SCHEMBL44000) 0.48 8/20
SCHEMBL124265 SCHEMBL124265 0.78 7/20
SCHEMBL124267 SCHEMBL124267 0.78 7/20
SCHEMBL124391 SCHEMBL124391 0.78 7/20
SCHEMBL124197 SCHEMBL124197 0.67 7/20
SCHEMBL125201 SCHEMBL125201 0.62 7/20
SCHEMBL124343 SCHEMBL124343 0.61 7/20
SCHEMBL179138 SCHEMBL179138 0.61 7/20
SCHEMBL125806 SCHEMBL125806 0.58 7/20
SCHEMBL125111 SCHEMBL125111 0.57 7/20
SCHEMBL125825 SCHEMBL125825 0.57 7/20
SCHEMBL31073 SCHEMBL31073 0.79 6/20
SCHEMBL124228 SCHEMBL124228 0.71 6/20
SCHEMBL179142 SCHEMBL179142 0.68 6/20

Clinical trials — most relevant to METAP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome PHASE4COMPLETED
Pharmacogenomic Evaluation of Antihypertensive Responses PHASE4COMPLETED
Naproxen Pharmacogenetic Study (Project 1, Aim 2) PHASE4UNKNOWN
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study) PHASE3COMPLETED
Efficacy and Safety of Alogliptin Plus Metformin in Patients With Type 2 Diabetes PHASE3COMPLETED
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults PHASE3COMPLETED
Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus PHASE2COMPLETED
Peptide Vaccine Focusing on Prevention of the Recurrence for Bladder Cancer PHASE2UNKNOWN
Novel Peptide Vaccination for Patients With Advanced Bladder Cancer PHASE1COMPLETED
The Study of Quadruple Therapy Quercetin, Zinc, Metformin, and EGCG as Adjuvant Therapy for Early, Metastatic Breast Cancer and Triple-negative Breast Cancer, a Novel Mechanism EARLY_PHASE1UNKNOWN
LRP1 and Colon Cancer nanUNKNOWN
Family Blood Pressure Program - SAPPHIRe Network nanCOMPLETED
Family Blood Pressure Program - GenNet Network nanCOMPLETED
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
Family Blood Pressure Program - HyperGEN nanCOMPLETED
Pharmacogenomic Response to Thyrotropin-Releasing Hormone Stimulation in Healthy Volunteers: The Influence of a Common Type 2 Deiodinase Genetic Polymorphism on Serum T3 nanCOMPLETED
Genetic Variants and Regulation of Specialized Pro-resolving Mediator nanRECRUITING
PROOF: Pancreatitis-associated Risk Of Organ Failure nanCOMPLETED
HSD3B1 Gene Polymorphisms With Outcomes in SARS-CoV-2 Infected Patients nanCOMPLETED
Dietary Effects of Sulfur Amino Acids nanCOMPLETED
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS nanCOMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study nanCOMPLETED
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC nanCOMPLETED
Proteomics of Primary Hyperoxaluria Type 1 nanCOMPLETED
Genetic Basis of Mitral Valve Prolapse nanUNKNOWN
Observational Study of Sepsis and Pneumonia to Develop Diagnostic Tests nanUNKNOWN
The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis nanRECRUITING
Characterization of Microbiological and Genetic Features in Prostate Cancer and Their Association with Disease Stage nanENROLLING_BY_INVITATION
Genetic Characterization of Parkinson's Disease nanCOMPLETED
Molecular & Clinical Evaluation of Low HDL Syndromes nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a METAP1 binder may also engage these)

ProteinNameSimilarity
Q5RBF3 1.000 Q5RBF3 →
Q8BP48 1.000 Q8BP48 →
Q5ZIM5 1.000 Q5ZIM5 →
A6QLA4 1.000 A6QLA4 →
Q5I0A0 1.000 Q5I0A0 →
Q4QRK0 1.000 Q4QRK0 →
Q9SLN5 1.000 Q9SLN5 →
Q7ZWV9 0.999 Q7ZWV9 →
O59730 0.996 O59730 →
Q54WU3 0.992 Q54WU3 →
Q9FV50 0.990 Q9FV50 →
Q9CPW9 0.990 Q9CPW9 →
O08663 0.989 O08663 →
Q4VBS4 0.989 Q4VBS4 →
Q56Y85 0.987 Q56Y85 →
Q6UB28 0.987 Q6UB28 →
C5DE35 0.987 C5DE35 →
D8PR70 0.985 D8PR70 →
Q01662 0.985 Q01662 →
O60085 0.985 O60085 →
Q9FV52 0.984 Q9FV52 →
C1H9Q9 0.984 C1H9Q9 →
C9SB49 0.984 C9SB49 →
C0SIM8 0.983 C0SIM8 →
A4RDI6 0.983 A4RDI6 →
C5G874 0.983 C5G874 →
E3L3Q8 0.983 E3L3Q8 →
C1HAB2 0.983 C1HAB2 →
E5R3Z8 0.983 E5R3Z8 →
Q6CP80 0.982 Q6CP80 →